Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

-0.03 (0.09%)

as of Aug 4, 2026, 8:00:00 pm Market Open.

70 watching

Investor Insights

Aug 4, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) has garnered mixed reviews from various experts, reflecting a dynamic yet cautious outlook on its performance. In recent months, the stock has significantly appreciated, showing a 264% increase since early 2023 under the leadership of its current CEO. Despite this positive trajectory, experts express concerns regarding the erosion of prices in the GLP market as more generics come into play, which could impact Teva's profitability. While it has exhibited strong momentum and accumulated growth since breaking the $21 mark in September, there's skepticism about its level of innovation in an increasingly competitive pharmaceutical landscape. Analysts project a bullish target price of $34.50, underlining potential optimism despite the caveats presented in the commentary.

Consensus

Mixed

Valuation

Fair Value

Similar

Novartis, NVS

HOLD

Owns half as much as he used to. Worried about their biggest non-generic product. It’s an MS drug with a lot of controversy.

COMMENT

Generic drugs are going to thrive. Cost of drugs is killing global governments that pay for them. The solution is generics that typically cost a fraction. He is wary of the entire pharmaceutical industry.

TOP PICK

Likes the generic space. Expects there will be increasing appetite for governments globally to spend less on health care. Have some very aggressive growth targets for the next 4-5 years. Have been very good at doing acquisitions.

PAST TOP PICK

(A Top Pick May 6/09. Up 37% excluding dividends.) Largest global generic manufacturer. Made acquisitions that strengthens them geographically. Trend towards generics is going to continue.

TOP PICK

Largest manufacturer of generic drugs. Have a pipeline potential of over $100 billion over the next 5 years as patents come off from large pharmaceuticals. Seriously undervalued.

DON'T BUY

Half business is generic drugs. US health care companies are reporting. New US reform will cause increased rebates to Medicaid. This is primary reason for TEVA coming off along with the group.

COMMENT

Generics continue to get wins in terms of shortened time frames as to pharmaceuticals staying on patents.

PAST TOP PICK

(A Top Pick Jan 28/09. Up 34.77%.) Buy on weakness.

TOP PICK

Dominant generics player globally. Has 25% of the generic market in the US. Expecting some form of health care will pass in the US, which will bring 20-40 million people into the health-care system. Trading at only about 15X earnings. Very strong growth prospects.

PAST TOP PICK

(A Top Pick Nov 11/08. Up 24.69%.) Still likes.

BUY

More and more major drugs are coming off patent over the next few years. Being the biggest they will get the lion’s share.

TOP PICK

(A Top Pick May 11/09. Up 12.75%.) Has been in a great uptrend for many years. Thinks you will be able to buy this on a pullback within the next 30 days or so. Fundamentals are good on this company.

PAST TOP PICK

(A Top Pick Oct 14/08. Up 23.38%.) World's largest generic drug company. Also have some branded drugs that are doing very well.

COMMENT

Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.)

BUY

World's largest manufacturer of generic drugs. Also has its own patented proprietary drugs. Has grown through acquisitions and by taking advantage of the drugs that are coming off patent.

Showing 181 to 195 of 276 entries

Most Recent Experts

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

The Monthly Gems by Allan Tong

Stockchase

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)